Long-term Outcomes Following Artificial Urinary Sphincter Placement: An Analysis of 1082 Cases at Mayo Clinic
Affiliations
Objective: To evaluate long-term device outcomes following primary artificial urinary sphincter (AUS) implantation.
Materials And Methods: We identified 1802 male patients with stress urinary incontinence that underwent AUS placement from 1983 to 2011. Of these, 1082 (60%) were involving primary implantations and comprise the study cohort. Multiple clinical and surgical variables were evaluated for potential association with treatment failure, defined as any secondary surgery. Patient follow-up was obtained through office examination, operative report, and written or telephone correspondence.
Results: Patients undergoing AUS implantation had a median age of 71 years (interquartile range 66-76) and median follow-up of 4.1 years (interquartile range 0.8-7.7). Overall, 338 of 1082 patients (31.2%) underwent secondary surgery, including 89 for device infection and/or erosion, 131 for device malfunction, 89 for urethral atrophy, and 29 for pump malposition or tubing complications. No patient-related risk factors were independently associated with an increased risk of secondary surgery on multivariable analysis. Secondary surgery-free survival was 90% at 1 year, 74% at 5 years, 57% at 10 years, and 41% at 15 years.
Conclusion: Primary AUS implantation is associated with acceptable long-term outcomes. Recognition of long-term success is important for preoperative patient counseling.
Deol E, Jefferson F, Fadel A, Sharma V, Blezek D, Elliott D Transl Androl Urol. 2024; 13(10):2238-2245.
PMID: 39507861 PMC: 11535732. DOI: 10.21037/tau-24-342.
Artificial urinary sphincter for neurogenic urinary incontinence: a narrative review.
Findlay B, Elliott D Transl Androl Urol. 2024; 13(8):1738-1743.
PMID: 39280676 PMC: 11399043. DOI: 10.21037/tau-22-794.
Rigicon ContiClassic and ContiReflex artificial urinary sphincter devices.
Koca O, Guzel R, Kirkik D, Karaman M, Chung E Transl Androl Urol. 2024; 13(8):1762-1766.
PMID: 39280675 PMC: 11399054. DOI: 10.21037/tau-23-464.
Madanelo M, Chartier-Kastler E, Greenwell T, Gray G, Khavari R, van Koeveringe G Transl Androl Urol. 2024; 13(8):1674-1686.
PMID: 39280667 PMC: 11399035. DOI: 10.21037/tau-23-58.
Ameli G, Husch T, Hubner W, Weibl P Transl Androl Urol. 2024; 13(8):1546-1554.
PMID: 39280656 PMC: 11399051. DOI: 10.21037/tau-22-779.